UBS AG Analysts Give Novartis AG (NOVN) a CHF 78 Price Target
UBS AG set a CHF 78 price objective on Novartis AG (VTX:NOVN) in a research report sent to investors on Monday, www.boersen-zeitung.de reports. The brokerage currently has a neutral rating on the stock.
Several other equities analysts also recently weighed in on NOVN. Deutsche Bank AG set a CHF 78 price target on shares of Novartis AG and gave the stock a neutral rating in a research note on Wednesday, June 21st. HSBC Holdings plc set a CHF 85 price target on shares of Novartis AG and gave the stock a buy rating in a research note on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on shares of Novartis AG and gave the stock a neutral rating in a research note on Wednesday, June 21st. Jefferies Group LLC set a CHF 100 price target on shares of Novartis AG and gave the stock a buy rating in a research note on Monday, June 5th. Finally, Barclays PLC set a CHF 65 price target on shares of Novartis AG and gave the stock a sell rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the stock. Novartis AG currently has a consensus rating of Hold and a consensus price target of CHF 84.67.
Novartis AG (NOVN) opened at 79.25 on Monday. The company has a 50-day moving average price of CHK 80.87 and a 200-day moving average price of CHK 78.05. The company has a market cap of CHK 185.67 billion and a PE ratio of 28.93. Novartis AG has a 1-year low of CHK 67.40 and a 1-year high of CHK 84.35.
TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/31/ubs-ag-analysts-give-novartis-ag-novn-a-chf-78-price-target.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.